0001104659-26-042886
SEC filingHarmony Biosciences Holdings, Inc. announced the departure of CFO Sandip Kapadia effective April 14, 2026, and appointed Glenn Reicin as new CFO on the same date, issuing a press release reiterating 2026 net revenue guidance of $1.0 to $1.04 billion.
Harmony Biosciences Holdings, Inc. disclosed a significant leadership transition with the immediate departure of CFO Sandip Kapadia on April 14, 2026, to pursue other opportunities, accompanied by a generous severance package including a $539,000 lump-sum payment, tax-grossed COBRA coverage, outplacement services, and accelerated vesting of specific equity awards. This change coincides with the appointment of experienced biotech executive Glenn Reicin as the new CFO, effective the same date. Reicin, aged 61, brings substantial credentials from roles at Eccogene, Alladapt Immunotherapeutics, Sigilon Therapeutics, and Morgan Stanley, positioning him to oversee finance, investor relations, and strategic growth. His compensation package features a competitive $500,000 base salary, 50% target bonus tied to performance, and a $3 million stock option vesting over four years, with robust severance protections including 12 months of pay and benefits if terminated without cause or for good reason, enhanced further around a change of control. The company supported the announcement with a press release (Exhibit 99.1) that not only highlights Reicin's track record in capital markets and growth but also reaffirms its 2026 net product revenue guidance of $1.0 to $1.04 billion from WAKIX sales, signaling continuity in financial outlook and strategic priorities amid the transition.